Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stigma Reduction Intervention for MSM and Healthcare Providers

13 novembre 2026 aggiornato da: Toan Ha, University of Pittsburgh

Adapting an Intervention to Reduce Stigma Among MSM and Healthcare Providers in Vietnam

This study describes only the Aim 2 clinical trial component of the NIH-funded project "Adapting an Intervention to Reduce Stigma among MSM and Healthcare Providers in Vietnam". The purpose of this pilot randomized waitlist-controlled trial (N=180) is to evaluate the preliminary efficacy of DONGHANH, a stigma-reduction intervention for men who have sex with men and healthcare providers in Vietnam. The study will provide preliminary data on the intervention's potential impact to inform the design of a larger future trial evaluating its effects on HIV prevention and care outcomes in Vietnam and in other countries with collectivist cultures.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a pilot randomized waitlist-controlled trial of DONGHANH, a stigma-reduction intervention for men who have sex with men (MSM) and healthcare providers (HCP) in Vietnam. Participants are randomized 1:1 to receive DONGHANH immediately or to a waitlist control. Waitlist participants receive the same DONGHANH workshops after the 3-month assessment. Assessments occur at baseline and 3 months for all participants. Participants in the immediate intervention arm complete an additional assessment at 6 months. Efficacy outcomes are analyzed using generalized linear mixed models or generalized estimating equations, with the intervention-by-time interaction as the primary test of effect.

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Toan Ha, MD, DrPH
  • Numero di telefono: 412-383-4576
  • Email: toh33@pitt.edu

Luoghi di studio

      • Hanoi, Vietnam
        • Institute of Social and Medical Studies
        • Contatto:
          • Nam T Nguyen, MD, DrPH
          • Numero di telefono: +84-02435558288
          • Email: ntnam@isms.org.vn

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

MSM:

  • Age 18 years or older
  • Cisgender male
  • HIV-positive, HIV-negative, or unknown HIV status
  • Self-reported history of condomless sex
  • Able to provide written informed consent

Healthcare providers:

  • Age 18 years or older
  • Works in an HIV outpatient clinic or community-based organization clinic in Hanoi
  • Able to provide informed consent

Exclusion Criteria:

  • Unable to provide informed consent
  • Unable to read and understand Vietnamese
  • Currently enrolled in another HIV intervention study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: DONGHANH Intervention

DONGHANH is a stigma-reduction intervention for men who have sex with men (MSM) and healthcare provider (HCP) in Vietnam. The intervention is delivered through five workshops attended jointly by MSM and HCP participants. Each workshop lasts approximately 1.5 days and consists of 10 modules. The modules use presentations, group discussions, and interactive exercises to build understanding of HIV-related and sexuality-related stigma; facilitate the sharing of personal experiences of stigma among MSM and HCP participants; explore the health effects of stigma; and develop strengths and strategies for coping with and reducing stigma.

DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies.

Sperimentale: Waitlist control group

Participants in this arm receive no intervention for the first 3 months after randomization. During this period, study staff contact them every 2 weeks to maintain retention. These contacts do not include any intervention content. After the 3-month assessment, participants receive the same DONGHANH workshops Assessments occur at baseline, 3 months and 6 months

DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Feasibility of the intervention
Lasso di tempo: 3 months

Feasibility of the intervention will be assessed with the feasibility of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater perceived feasibility. Results will be reported separately for among MSM and healthcare providers.

3 months
Acceptability of of the intervention
Lasso di tempo: 3 months

Acceptability of the intervention will be assessed with the acceptability of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater acceptability. Results will be reported separately for MSM and healthcare providers.

3 months
Appropriateness of the intervention
Lasso di tempo: 3 months

Appropriateness of the intervention will be assessed using the intervention appropriateness measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The overall score is calculated as the mean of the four items, ranging from 1 to 5. Higher scores indicate greater perceived appropriateness. Results will be reported separately for MSM and healthcare providers.

3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in stigma
Lasso di tempo: Baseline, 3 months, and 6 months

Change in stigma will be measured using the homosexuality-related stigma scale (Vietnamese version), a self-report measure of stigma among MSM. The scale has three subscales: enacted stigma (7 items, rated 1 [never] to 4 [many times]), perceived stigma (11 items), and internalized stigma (8 items). Perceived and internalized stigma items are rated 1 (strongly disagree) to 4 (strongly agree). Each subscale score is the mean of its items and ranges from 1 to 4. Higher scores indicate greater stigma. Change is calculated as the 3-month and 6- month score minus the baseline score.

Baseline, 3 months, and 6 months
Change in observed HIV-related stigma in healthcare settings
Lasso di tempo: Baseline, 3 months, and 6 months

Change in observed HIV-related stigma will be measured using 3 items assessing HIV-related stigma among health facility staff. Items ask how often participants observed stigmatizing behaviors in their health facility in the past 12 months (for example, health workers unwilling to care for a patient living with HIV). Each item is rated on a 4-point frequency scale: 1 (never), 2 (once or twice), 3 (several times), and 4 (most of the time). The score is the sum of the 3 items and ranges from 3 to 12. Higher scores indicate more observed stigma.

Baseline, 3 months, and 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Toan Ha, MD, DrPH, University of Pittsburgh

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 aprile 2027

Completamento primario (Stimato)

15 luglio 2027

Completamento dello studio (Stimato)

1 marzo 2029

Date di iscrizione allo studio

Primo inviato

13 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • STUDY26010095
  • R01TW013193 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data (IPD) underlying the results reported in publications will be deposited in an NIH-supported repository for HIV-related behavioral research. Access will be controlled and subject to a data use agreement prohibiting re-identification and unauthorized disclosure. Given the sensitive nature of HIV-related information and sexual orientation, and the risk of re-identification in small samples, data will be reviewed and de-identified before sharing. Data will be made available in accordance with repository policies and applicable consent, ethical, and institutional requirements, for as long as the repository maintains the data and makes them available.

Periodo di condivisione IPD

Data underlying published results will be available upon publication. Any other Aim 2 data will be shared by the end of the award period at the latest. Data will remain available in the repository for a minimum of 7 years.

Criteri di accesso alla condivisione IPD

Data will be available free of charge through the Mendeley Data repository. Users must register with the repository and agree to its terms, which restrict use to scientific research and aggregate statistical reporting. Data will be findable through a digital object identifier assigned by the repository. Access will follow the informed consent and institutional requirements, and any data designated as restricted use will be available under the repository's restricted-access terms.

Tipo di informazioni di supporto alla condivisione IPD

  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .